TY - JOUR
KW - Anaphylactic reactions
KW - Dipeptidyl peptidase-4 inhibitors
KW - Glucagon-like peptide-1 receptor agonists
KW - pharmacoepidemiology
KW - Sodium-glucose cotransporter-2 inhibitors
AU - R. Pradhan
AU - E. Patorno
AU - H. Tesfaye
AU - S. Schneeweiss
AU - H. Yin
AU - J. Franklin
AU - A. Pawar
AU - C. Santella
AU - O. H. Y. Yu
AU - C. Renoux
AU - L. Azoulay
AD - Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Québec, Canada.
Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Québec, Canada.
Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Division of Endocrinology, Jewish General Hospital, Montreal, Québec, Canada.
Department of Neurology and Neurosurgery, McGill University, Montreal, Québec, Canada.
Gerald Bronfman Department of Oncology, McGill University, Montreal, Québec, Canada.
AN - 35136902
BT - Am J Epidemiol
DO - 10.1093/aje/kwac021
DP - NLM
ET - 2022/02/10
LA - eng
N1 - 1476-6256
Pradhan, Richeek
Patorno, Elisabetta
Tesfaye, Helen
Schneeweiss, Sebastian
Yin, Hui
Franklin, Jessica
Pawar, Ajinkya
Santella, Christina
Yu, Oriana H Y
Renoux, Christel
Azoulay, Laurent
Journal Article
United States
Am J Epidemiol. 2022 Feb 5:kwac021. doi: 10.1093/aje/kwac021.
PY - 2022
SN - 0002-9262
T2 - Am J Epidemiol
TI - Glucagon-Like Peptide-1 Receptor Agonists and Risk of Anaphylactic Reaction Among Patients With Type 2 Diabetes: Multisite Population-Based Cohort Study
ER -